Repligen

Repligen Market capitalization

The The market capitalization of Repligen (RGEN) as of Oct 24, 2026 is 7.68 B USD. In the previous year, The market capitalization was 7.68 B USD — a change of 0.00% (lower).

Market capitalization

7.68 BUSD

YoY

0.00%

Last updated:

In 2025, Repligen's market cap stood at 7.68 B USD, a 0.00% increase from the 7.68 B USD market cap in the previous year.

The Repligen Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2018
7.68 B USD
Jan 1, 2019
7.68 B USD
Jan 1, 2020
7.68 B USD
Jan 1, 2021
7.68 B USD
Jan 1, 2022
7.68 B USD
Jan 1, 2023
7.68 B USD
Jan 1, 2024
7.68 B USD
Jan 1, 2025
7.68 B USD
The Repligen Market capitalization history
YEARMarket capitalizationYoY
7.68 BUSD0.00%
7.68 BUSD0.00%
7.68 BUSD0.00%
7.68 BUSD0.00%
7.68 BUSD0.00%
7.68 BUSD0.00%
7.68 BUSD0.00%
7.68 BUSD0.00%
7.68 BUSD0.00%
7.68 BUSD0.00%
7.68 BUSD0.00%
7.68 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Repligen Stock analysis

What does Repligen do? Repligen Corp is an American company that was founded in 1981 and is headquartered in Waltham, Massachusetts. The company is a leading provider of products for the biopharmaceutical industry. It offers a wide range of innovative products and services that contribute to the acceleration and improvement of the development of biological drugs. The history of Repligen Corp begins in the 1980s when the company was originally founded to produce human proteins for medical purposes. Over the years, the company expanded its business and focused on the production of purification solutions for the biopharmaceutical industry. Today, Repligen is an established company in this field and serves customers around the world. Business model: Repligen Corp is a leading provider of products and services for the biopharmaceutical industry. The company focuses on the development and manufacturing of products for the purification of proteins and antibodies. These products are used by biotech and pharmaceutical customers to improve the effectiveness and safety of their products in the clinical development process. Repligen Corp is generally able to achieve good prices for its products as they are high-quality products for a high-priced industry. The company is also interested in introducing new products to the market and expanding its customer base. Various divisions: Repligen Corp offers a wide range of innovative products and services that contribute to the acceleration and improvement of the development of biological drugs. The company is divided into various divisions, including: 1. Chromaflow: Repligen's Chromaflow products offer a wide range of purification solutions for proteins and antibodies used in the biopharmaceutical industry. These products enable customers to test and develop their products faster and more effectively. 2. Protein A Adsorbent Resin: Repligen Corp offers a Protein A Adsorbent Resin used in biotherapy. It allows for highly efficient purification of therapeutics produced using Protein A. 3. Alternating Tangential Flow (ATF) Systems: Repligen's ATF system enables continuous cell culture of proteins and antibodies. This facilitates the production of biopharmaceutical products and shortens development time. 4. Process Analytical Technology (PAT): Repligen Corp's PAT system allows for accurate monitoring of the manufacturing process of biopharmaceutical products. It improves process control and reduces the risk of errors and failures. 5. Filtration products: Repligen's filtration products include disposable filters and microfiltration membranes. These products are used by customers in the biopharmaceutical industry for the purification of biological products. Products: Repligen Corp offers a wide range of innovative products and services to support the development of biological drugs. Here are some of the products offered by Repligen Corp: 1. Protein A Adsorbent Resin: This product is used in biotherapy and the biopharmaceutical industry to enable highly efficient purification of therapeutics produced using Protein A. 2. Alternating Tangential Flow (ATF) Systems: This system enables continuous cell culture of proteins and antibodies. It facilitates the production of biopharmaceutical products and shortens development time. 3. Chromaflow products: They offer a wide range of purification solutions for proteins and antibodies used in the biopharmaceutical industry. 4. PAT systems: Repligen Corp's PAT system allows for accurate monitoring of the manufacturing process of biopharmaceutical products. 5. Filtration products: Repligen's filtration products include disposable filters and membranes. These products are used by customers in the biopharmaceutical industry to purify biological products. In summary, Repligen Corp is an established company that focuses on the development and production of products and services for the biopharmaceutical industry. The company offers a wide range of innovative products that contribute to the acceleration and improvement of the development of biological drugs. With its long history and established reputation as a leading provider, Repligen Corp is a significant player in the biopharmaceutical industry. Repligen is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Repligen's Market Capitalization

Repligen's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Repligen's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Repligen's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Repligen’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Repligen stock

The market capitalization of Repligen is 7.68 B USD in 2025.

The market capitalization of Repligen changed from 7.68 B USD to 7.68 B USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Repligen since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Repligen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Repligen

All Key Metrics — Repligen